To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

Charles A. Sanders, M.D., Scientific Symposium

Under Dr. Charles A. Sanders’ visionary leadership, the FNIH has influenced the course of biology and medicine over the past 20 years. At the Charles A. Sanders, M.D., Scientific Symposium, hear from scientific leaders, including Lurie Prize in Biomedical Sciences awardees, to learn more about the latest pioneering biomedical research.

Precision Medicine Initiative Survey

Informing the development of the Precision Medicine Initiative.

Advancing Science, Improving Lives - NINR's 30th Anniversary Events

Celebrating the 30th Anniversary of the National Institute of Nursing Research (NINR), the Advancing Science, Improving Lives symposia and scholarly events will bring together scientists, healthcare professionals and members of the public to discuss the advancements in nursing science that build the foundation of clinical nursing practice.

Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development (MAL-ED)

The study was implemented using shared and harmonized protocols across the eight sites to gather an enormous amount of data (physical, cognitive assessments, diet, illness and enteric infection, socio-economic status, etc.) to enable identification and characterization of factors associated with negative impacts on a child’s growth, development and vaccine response early in life.

Biomarkers Consortium - Workshop: Developing an Evidentiary Criteria Framework for Safety Biomarkers Qualification

This workshop aimed at creating alignment among scientific stakeholders including the FDA, the NIH, the biopharmaceutical industry, academic researchers and patient groups regarding a proposed framework for determining the levels of evidence required to qualify biomarkers for use in drug development.

Biomarkers Consortium - Use of Targeted Multiplex Proteomic Strategies to Identify Plasma-Based Biomarkers in Alzheimer’s Disease

The Biomarkers Consortium’s Targeted Plasma-Based Biomarkers in Alzheimer’s Disease (AD), completed in July 2012, was the first part of a multi-phased effort utilizing samples from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to validate multiplex panels in both plasma and cerebrospinal fluid (CSF), to diagnose patients with AD and to monitor disease progression.